SCHEMBL5407237

SCHEMBL5407237

CC(C)COC(=O)N1CCCC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
HPGD P15428 1/20 0.52
KMT2A Q03164 1/20 0.52
RAB9A P51151 1/20 0.51
KIT P10721 1/20 0.44
PRMT5 O14744 2/20 0.41
WDR77 Q9BQA1 2/20 0.41
TSHR P16473 3/20 0.41
ALDH1A1 P00352 3/20 0.40
POLB P06746 2/20 0.40
P2RX4 Q99571 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HRH2 P25021 1/20 0.40
HRH1 P35367 1/20 0.40
THRB P10828 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3768429 0.98 KMT2A (0.55) MEN1HPGDKMT2ARAB9AKIT
SCHEMBL12233216 0.96 RAB9A (0.51) MEN1HPGDKMT2ARAB9AKIT
SCHEMBL16965427 0.86 MEN1 (0.43) MEN1HPGDKMT2ARAB9AKIT
SCHEMBL17092977 0.86 MEN1 (0.41) MEN1HPGDKMT2ARAB9APRMT5
SCHEMBL1873610 0.84 RAB9A (0.43) MEN1HPGDKMT2ARAB9AKIT
SCHEMBL21261796 0.84 MEN1 (0.45) MEN1HPGDKMT2ARAB9AKIT
SCHEMBL8921640 0.84 RAB9A (0.45) MEN1HPGDKMT2ARAB9AKIT
SCHEMBL28622902 0.84 MEN1 (0.40) MEN1HPGDKMT2ARAB9APRMT5
SCHEMBL3718960 0.83 RAB9A (0.52) MEN1HPGDKMT2ARAB9APRMT5
SCHEMBL4077922 0.83 MEN1 (0.44) MEN1HPGDKMT2ARAB9AKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104918939-B Purine inhibitors of human phosphatidylinositol 3-kinase 默沙东公司 2018-08-28 CN claimed
EP-0682663-A1 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-22 EP claimed
CN-120058702-A Heterocyclic TEAD inhibitors 武汉人福创新药物研发中心有限公司 2025-05-30 CN disclosed
US-20240067651-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS BIOHAVEN THERAPEUTICS LTD. 2024-02-29 US disclosed
US-20240067651-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS BIOHAVEN THERAPEUTICS LTD. 2024-02-29 US disclosed
WO-2023280280-A1 FUSED-RING COMPOUND THAT ACTS AS KRAS G12D INHIBITOR 微境生物医药科技(上海)有限公司 2023-01-12 WO disclosed
WO-2022188729-A1 FUSED RING DERIVATIVES USEFUL AS KRAS G12D INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-09-15 WO disclosed
US-20210395223-A1 PRODRUGS OF CGRP ANTAGONISTS PFIZER IRELAND PHARMACEUTICALS (IE) 2021-12-23 US disclosed
US-10968199-B2 Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2021-04-06 US disclosed
US-20200062727-A1 CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2020-02-27 US disclosed
EP-3327021-A1 JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF Yangji Chemical Co., Ltd. (KR) 2018-05-30 EP disclosed
US-20110189129-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-08-04 US disclosed
US-20110136765-A1 Pyrrolo[2,3-D]Pyrimidine Compounds PFIZER INC. (US) 2011-06-09 US disclosed
EP-2054416-B1 SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO KGAA (DE) 2011-01-05 EP disclosed
EP-2090576-A1 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators Merz Pharma GmbH & Co.KGaA (DE) 2009-08-19 EP disclosed
US-7189756-B2 Pyrrolidine derivatives HOFFMAN-LA ROCHE INC. (US) 2007-03-13 US disclosed
US-6790860-B2 USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION HOFFMANN-LA ROCHE INC. 2004-09-14 US disclosed
US-4234484-A FROM ALKOXYLATED CYCLIC AMIDES USING AS A CATALYST A QUATERNARY AMMONIUM OR ALKALI METAL SALT OF TETRAFLUOROBORIC OR HEXAFLUOROPHOSPHORIC ACID HOECHST AKTIENGESELLSCHAFT (DE) 1980-11-18 US disclosed
US-4149941-A ELECTROLYTIC ALKOXYLATION HOECHST AKTIENGESELLSCHAFT (DE) 1979-04-17 US disclosed
US-4118500-A Fungicidal alkoxy mono- and dialkoxy N-substituted cyclic amines HOECHST AKTIENGESELLSCHAFT (DE) 1978-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395223-A1 PRODRUGS OF CGRP ANTAGONISTS CALCRL, CALCA, CALCB MEN1 1015/4885HPGD 86/4885KMT2A 3669/4885
US-20200062727-A1 CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF BAD, BCL2, AIFM1 MEN1 4743/4885HPGD 2781/4885KMT2A 3618/4885
US-20110189129-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, HCCS, NSUN2 MEN1 4836/4885HPGD 2335/4885KMT2A 1664/4885
US-20110136765-A1 Pyrrolo[2,3-D]Pyrimidine Compounds JAK3, JAK1, JAK2 MEN1 4208/4885HPGD 1056/4885KMT2A 1256/4885
US-10968199-B2 Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof BAD, BCL2, AIFM1 MEN1 4743/4885HPGD 2781/4885KMT2A 3618/4885
US-20240067651-A1 PRODRUGS OF MYELOPEROXIDASE INHIBITORS MPO, CAT, SOD1 MEN1 3340/4885HPGD 137/4885KMT2A 1732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.